KR970032870A - 항산화제로서의 8,9-데하이드로에스트론의 용도 - Google Patents

항산화제로서의 8,9-데하이드로에스트론의 용도 Download PDF

Info

Publication number
KR970032870A
KR970032870A KR1019960061345A KR19960061345A KR970032870A KR 970032870 A KR970032870 A KR 970032870A KR 1019960061345 A KR1019960061345 A KR 1019960061345A KR 19960061345 A KR19960061345 A KR 19960061345A KR 970032870 A KR970032870 A KR 970032870A
Authority
KR
South Korea
Prior art keywords
dehydroestrone
salt
pharmaceutically acceptable
sulfate
inhibiting
Prior art date
Application number
KR1019960061345A
Other languages
English (en)
Other versions
KR100444002B1 (ko
Inventor
히토시 엔도우
카주하루 이에나가
도시히꼬 후지와라
마사아끼 미야모또
히로요시 호리꼬시
마사후미 기다카제
스티븐 제이 아델맨
Original Assignee
코니시 진우에몬
닛폰조키세야쿠 카부시키가이샤
원본미기재
상꾜 가부시끼가이샤
가와구치 시게키
오쓰카 세이야쿠 가부시키가이샤
버그 이곤 이
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코니시 진우에몬, 닛폰조키세야쿠 카부시키가이샤, 원본미기재, 상꾜 가부시끼가이샤, 가와구치 시게키, 오쓰카 세이야쿠 가부시키가이샤, 버그 이곤 이, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 코니시 진우에몬
Publication of KR970032870A publication Critical patent/KR970032870A/ko
Application granted granted Critical
Publication of KR100444002B1 publication Critical patent/KR100444002B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 항산화제로서 8,9-데하이드로에스트론 또는 8,9-데하이드로에스트론-3-설페이트 에스테르의 약제학적으로 허용되는 염을 사용하는 방법을 제공한다.

Description

항산화제로서의 8,9-데하이드로에스트론의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 항산화량의 8,9-데하이드로에스트론 또는 8,9-데하이드로에스트론-3-설페이트 에스테르의 약제학적으로 허용되는 염을 유리 라디칼에 의해 유도된 질병의 억제 또는 치료를 필요로 하는 포유동물에 투여하는 단계를 포함하여, 상기 질병을 억제 또는 치료하는 방법.
  2. 제 1항에 있어서, 3-설페이트 에스테르의 약제학적으로 허용되는 염이 알칼리 금속 염, 알칼리 토금속 염, 암모늄 염, 탄소수 1내지 6의 알킬아민 염 또는 각 알킬 그룹의 탄소수가 1 내지 6인 디알킬아민 염인 방법.
  3. 포유동물의 효소, 이온 채널, 구조 단백질 또는 막지질과 선택적으로 반응하고 유리 라디칼 반응을 억제하기에 충분한 양으로 대용 기질로서 8,9-데하이드로에스트론 또는 8,9-데하이드로에스트론-3-설페이트 에스테르의 약제학적으로 허용되는 염을 투여하는 단계를 포함하여, 효소, 이온 채널, 구조 단백질 및 막지질과의 유리 라디칼 반응의 억제 치료가 필요한 포유동물에서 상기 반응을 억제시키는 방법.
  4. 8,9-데하이드로에스트론 또는 8,9-데하이드로에스트론-3-설페이트 에스테르의 약제학적으로 허용되는 염을 투여하는 단계를 포함하여, 암, 중추신경계 장애, 골(bone) 질병, 노화, 염증성 장애, 말초 혈관 장애, 류마티스성 관절염, 자가면역 질병, 호흡곤란, 폐기종, 재관류 상해의 방지, 바이러스성 간염, 만성 활성 간염, 결핵, 건선, 전신성 홍반성낭창, 성인 호흡곤란증후군, 중추신경계 외상 및 발작 또는 재관류 과정동안 상해의 발병시 내인성 유리 라디칼 반응을 억제하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960061345A 1995-12-04 1996-12-03 항산화제로서8,9-데하이드로에스트론을포함하는약제학적조성물 KR100444002B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US793195P 1995-12-04 1995-12-04
US60/007,931 1995-12-04
US08/570,767 1995-12-12
JP95-349831 1995-12-20
JP95-338440 1995-12-26

Publications (2)

Publication Number Publication Date
KR970032870A true KR970032870A (ko) 1997-07-22
KR100444002B1 KR100444002B1 (ko) 2004-11-03

Family

ID=21728885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960061345A KR100444002B1 (ko) 1995-12-04 1996-12-03 항산화제로서8,9-데하이드로에스트론을포함하는약제학적조성물

Country Status (23)

Country Link
EP (1) EP0778025B1 (ko)
JP (1) JPH09169650A (ko)
KR (1) KR100444002B1 (ko)
CN (1) CN1104900C (ko)
AR (2) AR005866A1 (ko)
AT (1) ATE263565T1 (ko)
AU (1) AU703814B2 (ko)
BR (1) BR9605777A (ko)
CA (1) CA2191835A1 (ko)
CZ (1) CZ289780B6 (ko)
DE (1) DE69632117T2 (ko)
DK (1) DK0778025T3 (ko)
ES (1) ES2215187T3 (ko)
HK (1) HK1010095A1 (ko)
HU (1) HUP9603329A3 (ko)
IL (1) IL119744A (ko)
MX (1) MX9606009A (ko)
NO (1) NO312654B1 (ko)
NZ (1) NZ299858A (ko)
PT (1) PT778025E (ko)
SI (1) SI0778025T1 (ko)
SK (1) SK154296A3 (ko)
ZA (1) ZA969923B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
CN1832756A (zh) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
DE4334823C2 (de) * 1993-10-09 1998-09-17 Schering Ag Verfahren zur Herstellung von Schwefelsäurehalbestern von Estrogenen
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE19509729A1 (de) * 1995-03-13 1996-09-19 Schering Ag 17-Difluormethylen-Estratriene

Also Published As

Publication number Publication date
NO965165D0 (no) 1996-12-03
IL119744A0 (en) 1997-03-18
BR9605777A (pt) 1998-08-25
DK0778025T3 (da) 2004-06-07
KR100444002B1 (ko) 2004-11-03
NZ299858A (en) 2001-03-30
NO965165L (no) 1997-06-05
ATE263565T1 (de) 2004-04-15
HK1010095A1 (en) 1999-06-11
CN1158725A (zh) 1997-09-10
ZA969923B (en) 1998-05-26
SI0778025T1 (en) 2004-08-31
AR005866A1 (es) 1999-07-21
ES2215187T3 (es) 2004-10-01
AU703814B2 (en) 1999-04-01
CZ353296A3 (en) 1997-08-13
PT778025E (pt) 2004-08-31
CN1104900C (zh) 2003-04-09
AU7194496A (en) 1997-06-12
EP0778025B1 (en) 2004-04-07
DE69632117D1 (de) 2004-05-13
HUP9603329A2 (en) 1997-08-28
CZ289780B6 (cs) 2002-04-17
AR059965A2 (es) 2008-05-14
SK154296A3 (en) 1997-08-06
HUP9603329A3 (en) 1998-01-28
MX9606009A (es) 1997-08-30
JPH09169650A (ja) 1997-06-30
NO312654B1 (no) 2002-06-17
EP0778025A1 (en) 1997-06-11
DE69632117T2 (de) 2004-08-26
HU9603329D0 (en) 1997-01-28
IL119744A (en) 2003-01-12
CA2191835A1 (en) 1997-06-05

Similar Documents

Publication Publication Date Title
ATE73137T1 (de) 11-arylsteroid-derivate.
EP0139535A3 (en) Compositions for combatting toxaemia
ES8504666A1 (es) Un procedimiento para la preparacion de nuevas 1,2,3,4-tetrahidro-2-naftilaminas.
KR970032870A (ko) 항산화제로서의 8,9-데하이드로에스트론의 용도
PT87322A (pt) Novel 11-aryloestrane and 11-arylpregnane derivates
ATE10099T1 (de) 3,8-dialkylxanthine, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ES8800261A1 (es) Un procedimiento para preparar esteres de acido androstano-17 b-carboxilico
Bendtzen Human Leukocyte Migration Inhibitory Factor (LIF) II. Partial Biochemical Characterization of the Substrate Specificities for This Lymphokine
ATE103926T1 (de) Lysoganglioside-derivate.
NZ336343A (en) Use of equilenin as an antioxidant
RU96122881A (ru) Способы подавления
MXPA94001822A (es) Derivados de acido aciloxihexanoico.
AU5982790A (en) New di-lysogangliosides derivatives
Dunlop et al. Methylxanthine effects on cyclic adenosine 3′: 5′ monophosphate phosphodiesterase activity in preparations of neonatal rat cerebellum: Modification by trifluoperazine
Leon et al. Possible role of BC-PL in enhancing 32Pi incorporation into mice brain phospholipids
IE821918L (en) Pyridine n-oxide compounds
US3031479A (en) Hydrazine derivatives
Szökö et al. Effect of 1-deprenyl on lipid peroxidation in rat brain homogenate
KAMEYAMA Studies on the Complement in Liver Disease Part 3. Studies on the messurement of complement titer by the 50% hemolytic method in liver damage
HASHIMOTO et al. Possible involvement of calmodulin in the induction of phosphodiesterase by cyclic adenosine 3', 5'-monophosphate in Dictyostelium discoideum
KR900004335A (ko) 간질환 치료제
IE44688L (en) Triazole derivatives.
SE8501692D0 (sv) Novel androstane-17beta-carboxylic acid esters
GB1128478A (en) Process for purifying unsaturated fatty acids
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070710

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee